Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Triumeq in Healthy Japanese Subjects
NCT02539576Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Area under the concentration-time curve from time zero to last quantifiable concentration, Area under the concentration-time curve from time zero extrapolated to infinite time and 5 more. Started Oct 2015; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02539576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02539576.